tirzepatide mash fda Nearly 62% achieve resolution without worsening of fibrosis with SEMA vs TIRZ vs RETA

Clinically-relevant weight loss is achieved independently of early weight loss response to once-weekly subcutaneous semaglutide 2.4 mg (STEP 4)

Nearly 60% of patients taking 10 mg or 15 mg achieved a 20% or greater reduction in body weight

New evidence is shedding more light over the complex physiology of GLP-1 in health and metabolic diseases

The molecule consists of a modified amino acid sequence based on the glucagon backbone and includes targeted substitutions that improve resistance to enzymatic degradation while maintaining receptor binding capability

During the remaining duration of medication beyond the first month, there is little noticeable difference in the occurrence probability of adverse events between the two administration routes